Miao Meng

Dr. Miao Meng


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
JWJunqi Wang
Junqi Wang
WFWenkai Fu
Wenkai Fu
NLNan Lu
Nan Lu
ZGZhijiang Guo
Zhijiang Guo
SOSang Bing Ong
Sang Bing Ong
MMMiao Meng
Miao Meng

1 January 2024 in International Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
TXTian Xia
Tian Xia
JYJiachi Yu
Jiachi Yu
YCYe Chen
Ye Chen
XCXing Chang
Xing Chang
MMMiao Meng
Miao Meng
Alcoholic liver disease (ALD) poses a substantial global health challenge, with its pathogenesis deeply rooted in mitochondrial dysfunction. Our study explores the pivotal roles of Phosphoglycerate mutase family member 5 (Pgam5) and Voltage-Dependent Anion Channel 1 (VDAC1) in the progression of ALD, providing novel insights into their interplay and impact on mitochondrial integrity. We demonstrate that Pgam5 silencing preserves hepatocyte viability and attenuates ethanol-induced apoptosis, underscoring its detrimental role in exacerbating hepatocyte dysfunction. Pgam5's influence extends to the regulation of VDAC1 oligomerization, a key process in mitochondrial permeability transition pore (mPTP) opening, mitochondrial swelling, and apoptosis initiation. Notably, the inhibition of VDAC1 oligomerization through Pgam5 silencing or pharmacological intervention (VBIT-12) significantly preserves mitochondrial function, evident in the maintenance of mitochondrial membrane potential and reduced reactive oxygen species (ROS) production. In vivo experiments using hepatocyte-specific Pgam5 knockout (Pgam5hKO) and control mice reveal that Pgam5 deficiency mitigates ethanol-induced liver histopathology, inflammation, lipid peroxidation, and metabolic disorder, further supporting its role in ALD progression. Our findings highlight the critical involvement of Pgam5 and VDAC1 in mitochondrial dysfunction in ALD, suggesting potential therapeutic targets. While promising, these findings necessitate further research, including human studies, to validate their clinical applicability and explore broader implications in liver diseases. Overall, our study provides a significant advancement in understanding ALD pathophysiology, paving the way for novel therapeutic strategies targeting mitochondrial pathways in ALD.

9 November 2025 in Cell Proliferation
Verified
Journal Article
Open access
WFWen kai Fu
Wen kai Fu
JWJunqi Wang
Junqi Wang
NLNan Lu
Nan Lu
ZGZhijiang Guo
Zhijiang Guo
SOSang Bing Ong
Sang Bing Ong
MMMiao Meng
Miao Meng
Mitochondrial quality control (MQC) impairment plays a central role in driving the pathogenesis of metabolism-associated steatotic liver disease (MASLD). Specifically, this is manifested as reduced mitophagy; increased mitochondrial fission and decreased fusion; and impaired mitochondrial biogenesis. Key pathological mechanisms of MASLD, such as hepatocyte apoptosis, pyroptosis, and ferroptosis, are activated under the influence of factors including free fatty acids (FFAs), oxidative stress, NLRP3 inflammasome activation, and gut microbiota imbalance. Meanwhile, the letter also lists novel potential therapeutic strategies targeting these pathways, including autophagy enhancers, mitochondrial dynamics regulators, biogenesis promoters, and ferroptosis inhibitors.

22 May 2026 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
WFWen kai Fu
Wen kai Fu
JWJunqi Wang
Junqi Wang
ZGZhijiang Guo
Zhijiang Guo
SOSang Bing Ong
Sang Bing Ong
YGYong Gao
Yong Gao
XCXing Chang
Xing Chang

4 August 2026 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
PDF file
WFWenkai Fu
Wenkai Fu
JWJunqi Wang
Junqi Wang
NLNan Lu
Nan Lu
ZGZhijiang Guo
Zhijiang Guo
SOSang-Bing Ong
Sang-Bing Ong
MMMiao Meng
Miao Meng
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than 1.66 billion people globally. This metabolic disorder shows strong connections with mitochondrial dysfunction and disrupted mitochondrial quality control (MQC) processes. Our review systematically analyzes the molecular mechanisms underlying the relationship between MQC and MASLD development. Research evidence indicates that impaired MQC regulation worsens three key pathological conditions: it intensifies liver fat accumulation, increases oxidative damage, and promotes inflammatory cell death through activating inflammatory signaling pathways, boosting reactive oxygen species generation, and triggering programmed cell death in hepatocytes. Current pharmacological interventions have shown mixed effects. Metformin, resveratrol, and empagliflozin have moderating effects on MQC homeostasis in experimental models, but their clinical application remains limited. The review further predicts two key systemic impacts of MASLD: it amplifies cardiovascular disease risk through links between organ systems, and it highlights the need to develop targeted regulation of the gut microbiota. Three major research challenges require urgent attention: first, clarifying the complex interactions between different MQC pathways; second, establishing clinical effectiveness through human trials; third, bridging the gap between laboratory findings and practical medical interventions. These priorities highlight the need for coordinated multidisciplinary research efforts to address this growing public health challenge.

20 April 2026 in Phytomedicine
Verified
Journal Article
Closed access
XCXing Chang
Xing Chang
YZYicong Zhang
Yicong Zhang
WXWenshi Xu
Wenshi Xu
ZGZhijiang Guo
Zhijiang Guo
SOSang Bing Ong
Sang Bing Ong
MMMiao Meng
Miao Meng